BRCA1 germline mutations may be associated with reduced ovarian reserve

Fertility and Sterility

Volumn 102, Issue 6, 2014, Pages 1723-1728

  Wang, Erica T ^a   Pisarska, Margareta D ^a   Bresee, Catherine ^a   Chen, Yii Der Ida ^b   Lester, Jenny ^a   Afshar, Yalda ^a   Alexander, Carolyn ^a   Karlan, Beth Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Antim llerian hormone; BRCA mutations; Ovarian reserve

Indexed keywords

MUELLERIAN INHIBITING FACTOR; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN;

ADULT; APOPTOSIS; ARTICLE; BODY MASS; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA DAMAGE; FAMILY HISTORY; FEMALE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OUTCOME ASSESSMENT; OVARIAN RESERVE; OVARY CANCER; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; TERTIARY CARE CENTER; TUMOR SUPPRESSOR GENE; BLOOD; GENETICS; MIDDLE AGED; MUTATION; STATISTICAL MODEL;

ADULT; ANTI-MULLERIAN HORMONE; BODY MASS INDEX; BRCA1 PROTEIN; BRCA2 PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MUTATION; OVARIAN RESERVE;

EID: 84921950193     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2014.08.014     Document Type: Article

References (41)

1. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
2. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97:2187-95.
3. American College of Obstetrics and Gynecology. ACOG practice bulletin no. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol 2008;111:231-41.
4. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2012;98:1407-15.
5. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000;408:429-32.
6. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
7. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010;28: 240-4.
8. Lin WY, Beattie M, Chen L, Oktay K, Crawford S, Cedars MI, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 2013;119: 1652-9.
9. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 2013;99:1724-8.
10. Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, Gorski B, Zielinska D, Toloczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006;100:59-63.
11. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5:172ra21.
12. Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer 2014;24:233-7.
13. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 2011;6:e22024.
14. Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012;97:1673-80.
15. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-9.
16. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007;22:2414-21.
17. Celik E, Bastu E, Dural O, Yasa C, Buyru F. Relevance of anti-Mullerian hormone on in vitro fertilization outcome. Clin Exp Obstet Gynecol 2013; 40:66-9.
18. Wenzel L, Osann K, Lester J, Kurz R, Hsieh S, Nelson EL, et al. Biopsychological stress factors in BRCA mutation carriers. Psychosomatics 2012;53:582-90.
19. La Marca A, Sighinolfi G, Papaleo E, Cagnacci A, Volpe A, Faddy MJ. Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS One 2013; 8:e57005.
20. Bentzen JG, Forman JL, Pinborg A, Lidegaard O, Larsen EC, Friis-Hansen L, et al. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reprod Biomed Online 2012;25:612-9.
21. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods 2010;362:51-9.
22. Li HW, Ng EH, Wong BP, Anderson RA, Ho PC, Yeung WS. Correlation between three assay systems for anti-Mullerian hormone (AMH) determination. J Assist Reprod Genet 2012;29:1443-6.
23. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123-9.
24. Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H. Elevated serum levels of anti-Mullerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand 2013;92:1369-74.
25. Box GEP, Cox DR. An analysis of transformation. J R Stat Soc 1964;26:211-43.
26. Ficicioglu C, Cenksoy PO, Yildirim G, Kaspar C. Which cut-off value of serum anti-Mullerian hormone level can predict poor ovarian reserve, poor ovarian response to stimulation and in vitro fertilization success? A prospective data analysis. Gynecol Endocrinol 2014;30:372-6.
27. Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008;23:1359-65.
28. Lee RK, Wu FS, Lin MH, Lin SY, Hwu YM. The predictability of serum anti-Mullerian level in IVF/ICSI outcomes for patients of advanced reproductive age. Reprod Biol Endocrinol 2011;9:115.
29. Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, et al. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J Clin Oncol 2014;32:1093-4.
30. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-72.
31. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001;114(Pt 20):3591-8.
32. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012;12:68-78.
33. Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001;7:273-82.
34. Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Weideman PC, et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol 2013;31:3920-5.
35. Dolleman M, Verschuren WM, Eijkemans MJ, Dolle ME, Jansen EH, Broekmans FJ, et al. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. J Clin Endocrinol Metab 2013;98:2106-15.
36. Su HI, Sammel MD, Freeman EW, Lin H, DeBlasis T, Gracia CR. Body size affects measures of ovarian reserve in late reproductive age women. Menopause 2008;15:857-61.
37. La Vignera S, Condorelli R, Bellanca S, La Rosa B, Mousavi A, Busa B, et al. Obesity is associated with a higher level of pro-inflammatory cytokines in follicular fluid of women undergoing medically assisted procreation (PMA) programs. Eur Rev Med Pharmacol Sci 2011;15:267-73.
38. Maccio A, Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications - a review. J Mol Med 2013;91: 1355-68.
39. van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JW, Schats R, van Leeuwen FE, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod 2010;25: 1520-7.
40. Parazzini F, Progetto Menopausa Italia Study Group. Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas 2007; 56:280-7.
41. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod 2012;27:594-608.